Morgan Stanley analyst Michael Ulz lowered the firm's price target on Zentalis to $4 from $8 and keeps an Equal Weight rating on the shares after the company reported Q3 earnings and highlighted progress with enrollment ongoing in the DENALI Part 2a study for azenosertib in platinum resistant ovarian cancer. The firm has fine tuned its azenosertib revenue estimates, having increased its PROC revenue estimate, removed revenues from non-gynecological indications and decreased its peak sales estimate to $511M from $867M previously.
